Use of CXCL9 as a Biomarker of Acthar Efficacy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Use of CXCL9 as a Biomarker of Acthar Efficacy — Stella

Home/Sarcoidosis/

View on ClinicalTrials.gov

Recruiting

Back to Sarcoidosis trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California

Key details

Phase

Post-approval study

Sponsor

University of California, San Francisco

Collaborators

Mallinckrodt

Enrollment target

~14 participants

Started

November 2022

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated May 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.